Monopar Therapeutics shares dip amid rising selling pressure

Traders Union
All News
Financial News
Monopar therapeutics slides 2.26% today

Highlights

Monopar Therapeutics shows a moderately bullish configuration, trading above short- and medium-term moving averages but below long-term resistance.
Technical indicators present a mixed picture, with supportive momentum and buyer dominance, but neutral trend strength and caution for potential overbought conditions.
Price is expected to range between $62.42 and $64.17 over the next week, with sideways movement likely unless $64.53 is reclaimed or $62.42 breaks.

Anton Kharitonov, expert at Traders Union, notes that MNPR remains technically constructive but faces underlying caution. Price action is struggling to reclaim the 200-day moving average, and momentum indicators show no decisive trend. Absence of any supporting news limits positive sentiment and may undermine buyer conviction. Rising short-term bearish pressure and increased volatility raise the risks of a deeper pullback. "Without strong catalysts or a clear technical breakout, I remain skeptical about sustained upside in MNPR this week."

Viktoras Karapetjanc, expert at Traders Union, sees Monopar Therapeutics preserving a bullish structure despite the current dip. Support from the 50-day and 20-day moving averages indicates underlying strength. While there is a lack of fresh news, technicals are positioned for renewed momentum if buyers reclaim $64.53. The market offers multiple setups within the identified volatility band. "Further growth is expected if the stock secures a close above $64.53 — the bullish case remains intact for agile traders."

Mixed momentum signals as price challenges 200-day resistance

Price action remains just under the 200-day moving average ($64.53), with immediate dynamic support seen near the Ichimoku Kijun level at $59.43 and resistance at the MA-200. Momentum readings are moderately supportive: the Moving Average Convergence Divergence (MACD) signals a buy, the Average Directional Index (ADX) is neutral, and both the Relative Strength Index (RSI) and Stochastic RSI are slightly bullish to neutral. The Commodity Channel Index (CCI) also reflects a neutral-to-bullish posture, with no clear daily overbought or oversold signals, while Bull/Bear Power (BBP) indicates continued buyer dominance but rising caution for overbought extremes. The Awesome Oscillator (AO) confirms recent upside. Intraday, the stock is down $1.47 or 2.26%, tracking near session lows after a small downside gap and heightened 2.36% volatility. Short-term momentum divergence exists, suggesting possible support, though intraday bearish pressure persists.

Earlier, analysts noted that Monopar Therapeutics was exhibiting robust bullish momentum, though caution was warranted given early signs of overbought conditions. The latest technical readings suggest that while upward bias is still present, further confirmation above the 200-day moving average is now essential for a decisive trend; a close below $62.42 could open the door for additional downside risk.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.